New Drugs & Clinical Trials Rules, 2019

Definition, statutory basis & need

• What they are — the New Drugs and Clinical Trials Rules, 2019 (NDCT 2019) are subordinate legislation notified under the Drugs and Cosmetics Act, 1940 (the parent Act) — a standalone, consolidated code for clinical trials, BA/BE studies, new-drug approval and Ethics Committees in India.
• Schedule Y heritage — they carved this regulation out of the old Drugs and Cosmetics Rules, 1945, replacing the regime that lived in Schedule Y with a dedicated modern instrument (KDT 8e, a 2018 text, still describes the pre-2019 Schedule-Y position).
• Commencement — in force from gazette publication on 19 March 2019, except Chapter IV (EC for Biomedical & Health Research), which commenced 180 days later (r.1(2)).
• Applicability (r.1(3)) — all new drugs, investigational new drugs, clinical trials, bioequivalence & bioavailability studies, and Ethics Committees in India.
• 2022 amendment — materially amended by G.S.R. 21(E) dated 18 Jan 2022 — refining definitions (Designated Registration Authority; BA/BE-centre clinical + analytical part) and Chapter-IV registration mechanics.
• Why the Rules exist — a regulatory answer to a decade of controversy over unethical trials, inadequate trial-injury compensation, and opaque/slow approval timelines — designed to make the system predictable (defined timelines + deemed approval), accountable (mandatory compensation + EC registration) and globally credible, while incentivising drugs discovered/developed in India.